Today it was reported that the EVP, Global Professional Svcs. of Medidata Solutions (MDSO), Daniel Patrick Shannon, exercised options to sell 19,725 MDSO shares at $13.99 a share, for a total transaction value of $1.48M.
Following Daniel Patrick Shannon’s last MDSO Sell transaction on November 12, 2014, the stock climbed by 31.5%. In addition to Daniel Patrick Shannon, one other MDSO executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Medidata Solutions’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $167 million and quarterly net profit of $14.32 million. In comparison, last year the company earned revenue of $141 million and had a net profit of $13.77 million. MDSO’s market cap is $4.57B and the company has a P/E ratio of 87.66. Currently, Medidata Solutions has an average volume of 214.7K.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $77.00, reflecting a 2.7% upside.
The insider sentiment on Medidata Solutions has been negative according to 58 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medidata Solutions, Inc. provides cloud based solutions for life sciences for customer’s clinical development processes including concept, conclusion, research optimization, and development investments. Its cloud-based technology including its unified platform, pioneering analytics, and clinical technology allows the development of new therapies pharmaceutical companies, biotech, and medical device firms, academic medical centers and contract research organizations around the world. It operates through the following geographical segments: United States, Japan, and Other. The company was founded by Glen M. de Vries, Edward F. Ikeguchi and Tarek A. Sherif in June 1999 and is headquartered in New York, NY.
